3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
8
Phase 2
5
Phase 1/2
3
Phase 4
2
Phase NA
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Conditions
Acquired Immunodeficiency Syndrome
2
Sarcoma, Kaposi
1
Opportunistic Infections
1
Inflammation
1
HIV Infections
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Coinfection
1
Interventions
Dexamethasone
56
Metformin
50
Cyclophosphamide
47
Saline Solution
39
Cytarabine
37
Cisplatin
36
Zoledronic Acid
34
Letrozole
34
Carboplatin
33
Sodium Chloride
32
Bupivacaine
31
Docetaxel
30
Bevacizumab
30
Vincristine
29
Methotrexate
29
Fluorouracil
28
Propofol
27
Capecitabine
27
Fentanyl
26
Doxorubicin
26
Rituximab
25
Drug Therapy
25
Dexmedetomidine
25
Prednisone
23
Paclitaxel
23
Oxaliplatin
21
Morphine
21
Gemcitabine
21
Radiotherapy
19
Prednisolone
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Interventional
×
Ritonavir
×
Clear all
NCT04183738
2020-11-10
i2-D²EFT
Kirby Institute
Phase 4
Withdrawn
NCT00444379
2014-08-20
ARKS
University of California, San Francisco
Phase 4
Completed
224 enrolled